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Abstract (Word count 246) 
Backgroud: The aim of this study was to examine the outcomes of 
oesophageal adenocarcinoma (OC) treatment with either surgery alone (S), or 
with neoadjuvant chemotherapy (NAC) followed by surgery (NACS), by 
means of propensity score (PS) regression analysis, in order to examine 
whether the benefits reported in the MRC OE02 trial were reproducible in UK 
cancer network clinical practice. 
Methods: Consecutive patients undergoing potentially curative treatment for 
OC in a regional cancer network were studied. Multiple regression models, 
including PS were developed to account for confounding factors and the 
primary outcome measure was disease-free (DFS) and overall survival (OS). 
Results: A cohort of 440 patients was included in a regression analysis 
controlling for confounders (176 S, 264 NACS). NACS was associated with 
positive margin status (NACS vs. S, 42.4% vs. 26.7%, p<0.05), poor 5-year 
DFS (32.1% vs. 56.9, p<0.001), and poor 5-year OS (27.5% vs. 47.3%, 
p<0.001). On regression adjustment based on propensity scores, NACS was 
not associated with DFS (p=0.220) or OS (p=0.431). Mandard tumour 
regression grade (TRG) was significantly associated with DFS (hazard ratio 
(HR) 0.21,95% CI 0.07-0.70) and OS (HR 0.27 (95% CI 0.13-0.59). Five-year 
DFS and OS related to TRG was 63.6 and 61.5% vs. 8.0 and 8.6% (p<0.001) 
for good and poor responders respectively.  
Conclusion: Prescribing NAC to all OC patients risks delay in effective 
treatment of patients who are relatively chemo-resistant, given the variability 
in pathological response. Identifying OC patients who derive the most NAC 
benefit should be the focus.   
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Introduction 
The optimum contemporary treatment strategy for patients diagnosed with 
oesophageal cancer (OC) is controversial but is universally multimodal in 
nature. The exact nature of the multimodal therapy differs in relation to global 
region and specific trial reports. For example, UK National guidance 
recommends neoadjuvant chemotherapy (NAC) followed by surgery1, but 
European guidance differs with the possible addition of radiotherapy2. 
Furthermore, in North America the favored regime includes NAC followed by 
surgery, potentially followed by adjuvant post-operative chemotherapy or 
chemoradiotherapy3.  
Randomized controlled trials attempting to establish any survival 
benefit in treatment with NAC followed by surgery (NACS) compared with 
surgery alone (S) have reported contrasting outcomes. In the two largest of 
these studies, the UK MRC OE02 trial reported a 5 year survival of 23.0% 
after NAC compared with 17.1% after S (Hazard Ratio (HR) 0.82; 95% CI, 
0.71 - 0.95 p=0.03)4, whereas the US RTOG 8911, US Intergroup 113 
reported equivalence5. A recent Cochrane Review considered these two 
studies to be of high quality with low risk of bias, and concluded that although 
NACS may offer a survival advantage over S, further research was required6. 
The method of Propensity score (PS) analysis is being increasingly 
reported in medical literature, since first described in 19837. It enables 
estimates of probability of undergoing a treatment given a vector of observed 
variables and is a powerful alternative to draw causal inference on 
observational data as compared with conventional case-mix adjustment. This 
is based on the adjustment made by PS for confounding factors (or baseline 
	 4	
characteristics), on the independent variable (for example, treatment option). 
Propensity scores are generated by a logistic regression model and aim to 
replace a group of baseline characteristics with one score. Following this, PS 
can be used in a number of analytical techniques, the most common being 
matching, stratification, and regression adjustment. In this way, treatment 
arms can be balanced in terms of important covariables allowing a fair 
comparison of treatments to be made8–10. Therefore, as much of the selection 
bias is adjusted for, PS provides a scientifically sound alternative to RCTs in 
situations where interventions cannot be randomly allocated for ethical and 
practical reasons8,9. In essence, PS balances the treatment arms in terms of 
important covariates allowing a fair comparison of the treatments to be made9, 
and such analyses are being increasingly reported in medical literature10–12. 
The aim of this study was to examine the outcomes of OC treatment with 
either surgery alone or with NAC followed by surgery, by means of propensity 
score regression analysis, in order to examine whether the benefits suggested 
in the MRC OE02 trial were reproducible in contemporary clinical practice in a 
UK regional cancer network. 
 
Materials and Methods 
The study included consecutive patients diagnosed with potentially curable 
oesophageal adeoncarcinoma, including Siewert type 1 and 2 junctional 
tumours, between 1 January 2003 and 30 June 2018, by a regional 
multidisciplinary team serving a population of 1.76 million. Clinical and 
pathological information was collected prospectively.  Preoperative staging 
involved computed tomography (CT), endoluminal ultrasonography (EUS) and 
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laparoscopy, if appropriate. More recently routine CT-PET imaging has been 
incorporated, for all patients diagnosed from 2009 onwards. All staging was in 
accordance with the UICC Tumour Nodes Metastasis Classification (TNM) 7th 
Edition.13 Pathological response to chemotherapy was determined using the 
Mandard Tumour Regression Grade (TRG) score and was recorded from 
pathology reports issued at the time of resection.14 The EUS examinations 
were either performed or supervised by one of two radiologists. Ethical 
approval was sought from the regional ethics committee, but the chair 
confirmed that individual patient consent was not required to report clinical 
outcomes alone and as such no formal approval was necessary. 
 
Surgery (S) with or without Neoadjuvant Chemotherapy (NAC) 
Prior to the publication of OE02 in 20024, the main curative treatment for EC 
patients was primary surgery. However, following this, in general, fit patients 
with tumours of stage T3 and equivocal T4, N0 and N1 were treated with 
neoadjuvant therapy before surgery.15 The majority of these patients received 
2 cycles of 80mg/m2 of Cisplatin and 1000mg/m2 of 5-Fu for 4 days. A 
minority received 4 cycles of Epirubicin (50mg/m2), Cisplatin (60mg/m2) and 
5-Fu (200 mg/m2) or Capecitabine (625mg/m2; ECF/X). Other slightly altered 
regimes were used depending on patient comorbidities or adverse reactions. 
CT, following the final dose of NAC and prior to surgery, was used to establish 
tumour response to NAC.16 Patients treated with neoadjuvant 
chemoradiotherapy were not included in this study.  
Less fit patients and those with radiologically perceived stage T1-T2, N0 
disease were considered for surgery alone. Most patients underwent standard 
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subtotal oesophagectomy as described by Lewis and Tanner17,18. Trans-Hiatal 
Oesophagectomy (THO) as described by Orringer19, was used selectively in 
patients with adenocarcinoma of the lower third of the oesophagus who had 
significant cardiorespiratory co-morbidity. A small selection of patients with 
junctional OC underwent an extended total-gastrectomy and D2 
lymphadenectomy. Oesophageal resection was defined as potentially curative 
when all visible tumour had been removed. Involvement of the circumferential 
resection margin was defined as the presence of tumour less than 1 mm from 
the circumferential margin20.  
 
Follow-up and Disease Recurrence 
All patients were reviewed every 3 months for the first year after 
oesophagectomy, and every 6 months thereafter. Disease recurrence was 
suspected clinically and confirmed with investigations, usually CT or 
endoscopy. Patterns of recurrence were defined as loco-regional, distant 
(metastatic), or both loco-regional and distant, when both were diagnosed at 
the same time. The time of recurrence was taken as the date of the 
confirmatory investigation. Death certification was obtained from the Office for 
National Statistics. 
 
Statistical Analysis 
Sample size calculation 
Sample size calculations were based on a pre study literature survey of 
(CRUK cancers statistics21), which indicated that the baseline 5-year survival 
rate of patients diagnosed with stage II OC was expected to be 40%, 
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compared with 20% in patients with stage III OC, and a 15% difference in 
survival would be a realistic expectation. Thus, a minimum of 276 patients 
were to be studied, providing 80% power to detect such a difference with 
p<0.050. 
 
Propensity score adjustment  
Propensity Scores were generated using a logistic regression model, and 
included all relevant independent variables thought to be potential 
confounding factors. These were considered by the regional multidisciplinary 
team and comprised patient demographics (age >70 yr., American Society of 
Anaesthesiology (ASA) grade, and gender), and clinical staging (cTNM) 
based on radiological assessment of T-stage and N-stage.22 Generated 
propensity scores were then used in a regression adjustment to estimate the 
effect of the exposure to treatment on disease-free (DFS) and overall survival 
(OS). 
 
Data analysis  
Complete case analysis was based on intention to treat, and the primary 
outcome measures were disease-free survival and overall survival. Secondary 
outcome measures included OC recurrence and post-operative morbidity. 
Patient clinicopathological factors were analysed between the treatment 
modalities by means of Chi-square or non-parametric tests. DFS for all 
patients was calculated using similar methodology to both the MRC OEO2 
and US Intergroup randomised trials, by measuring the period from a 
landmark time of 6 months after diagnosis to the date of recurrence. This 
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approach was adopted in the randomised trials, to allow for the variable 
interval to surgery following diagnosis, depending on whether NAC was 
prescribed4. As in the trials, events resulting in a failure to complete curative 
treatment such as not proceeding to surgery, open and close laparotomy, 
palliative resection, and in-hospital mortality, were assumed to have occurred 
at this landmark time, to maintain the intention to treat analysis. Overall 
Survival (OS) was measured from the date of diagnosis to date of death or 
censorship, whichever occurred first. Cumulative survival was calculated 
according to the method of Kaplan and Meier, and differences between 
groups were analysed with the log rank test. Univariable analyses examining 
factors influencing survival were initially examined, and those with 
associations found to be statistically significant (P<0.05) retained in a Cox 
proportional hazards model. Cox proportional hazards models (controlling for 
PS) were used to estimate the effect of the treatment on the outcomes, both 
DFS and OS. Data analysis was carried out using the Statistical Package for 
the Social Sciences version 25 (SPSS, Chicago, Illinois, USA).   
 
Results 
Four hundred and forty patients underwent radical treatment for OC consisting 
of oesophagectomy alone (n=176, 40%) or NAC followed by oesophagectomy 
(n=264, 60%). Oesophagectomy was performed using either a Trans-
Thoracic (TTO) n=188 (47.8%), Trans-Hiatal (THO) n=182 (46.3%), or an 
extended total gastrectomy n=23 (5.9%). The median age for patients was 71 
years (Interquartile range (IQR) 65-78), 368 (83.6%) were male and 72 
(16.4%) were female. The overall median lymph node harvest was 14 (IQR 9-
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20). Two hundred and twenty one (50.2%) patients developed post-operative 
morbidity, which was associated with 14 (3.2%) deaths within 30 days of 
surgery. During follow-up, 163 patients (37.0%) developed cancer recurrence 
and 246 patients (55.9%) died. Median follow-up of survivors was 60 (range 
6-60) months. Some 80.7% of patients were followed up for at least 5 years or 
until death. 
 
Variance in clinicopathological factors and perioperative outcomes in patients 
stratified to surgery or NAC followed by surgery 
The details of 440 patients related to treatment modality are shown in Table 1. 
The operative approach in the S cohort compared with the NACS cohort was 
TTO in 42 (23.9%), and 146 (55.3%) respectively (p<0.001), and THO in 114 
(64.8%), and 68 (25.8%) respectively (p<0.001). The incidence of open and 
close laparotomy was 9 (5.1%) for S patients, compared with 38 (14.4%) for 
NACS patients (p=0.002). Resection was potentially curative (R0) in 120 
(68.2%) following S, compared with 114 (43.2%) following NACS (p=0.001), 
and palliative (R1 or R2) in 56 (31.8%) following S, compared with 150 
(56.8%) following NACS (p<0.05). On histopathology, there was CRM 
involvement in 47 patients (26.7%) following S, compared with 112 patients 
(42.4%) following NACS (p<0.05). The operative mortality (deaths within 30 
days) was 8 (4.5%) following S, and 6 (2.3%) following NACS (p=0.183).  
 
Influence of NACS on Disease-free survival (DFS)  
The relationship between NAC and DFS can be found in table 3 and figure 1a. 
NACS was associated with poorer 2-year (50.0% vs. 70.8%, p<0.001) and 5-
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year survival (32.1% vs. 56.9%, p<0.001). On univariable analysis, 
neoadjuvant therapy was associated with poorer OS (HR 1.55 (95% CI 1.19-
2.02), p=0.001. However, on PS analysis, there was no statistical difference 
between the modalities (p=0.431). The only factor to predict DFS was pTNM 
stage (HR 3.27 (95% CI 2.27-4.72), p<0.001).  
 
Influence of NACS on Overall Survival (OS)  
The relationship between clinicopathological characteristics and OS can be 
found in table 3 and figure 1b. NACS was associated with poorer 2-year 
(48.3% vs. 64.4%, p<0.001) and 5-year survival (27.5% vs 47.3%, p<0.001). 
On univariable analysis, NACS was associated with poorer DFS (hazard ratio 
(HR 1.76 (95% confidence interval (CI) 1.26-2.46), p=0.001. However, on PS 
analysis, there was no statistical difference between the modalities (p=0.220). 
The only factor to predict OS was pTNM stage (HR 3.05 (95% CI 2.12-4.41), 
p<0.001).  
 
Relationship between tumour regression and survival 
The Mandard tumour regression grade was used to determine pathological 
response to NACS. Mandard TRG scores were available for 152 patients. 
Twenty-five patients (16.4%) had a good pathological response (TRG 1 and 
2) and the Mandard TRG groupings were TRG 1 n=20 (13.2%), TRG 2 n=5 
(3.3%), TRG 3 n=12 (7.9%), TRG 4 n=59 (38.8%), and TRG 5 n=56 (36.8%). 
Good Mandard TRG was associated with improved DFS (figure 2a, p=0.033) 
and OS (figure 2b, p<0.001). Five-year DFS was 63.6% in the good and 8.0% 
in the poor Mandard TRG groups (p<0.001). Similar findings were observed 
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for OS, with 61.5% of good responders and 8.6% of poor responding living for 
5 years (p<0.001). This equated to a HR of 0.21 (95% CI 0.07-0.70), p=0.010) 
for DFS and 0.27 (95% CI 0.13-0.59), p=0.001) for OS.  
 
Discussion 
This study represents the first comparison of the outcomes of oesophageal 
adenocarcinoma treatment with surgery alone or NAC followed by surgery, 
implementing propensity score analysis. The principal findings were that, 
following application of PS, DFS and OS were comparable for surgery and 
NAC followed by surgery, both clinically and statistically. There was nearly a 
2-fold difference in 5-year DFS and OS, with NACS being associated with 
poorer survival. Operative morbidity and mortality were higher following 
surgery alone, but this difference was not statistically significant. 
This study has several potential limitations. Clearly it is not a 
randomized controlled trial rendering it vulnerable to selection bias and 
confounding by case mix. Groups of patients were unbalanced in terms of age 
and stage of disease. The data collected is from a single regional network, 
rather than multicentre. As would be expected, the process and strategy of 
radiological staging has developed and improved over the 15-year time span 
of the study; CT equipment has advanced and therefore the quality of the 
staging may be inconsistent. In contrast, the EUS equipment utilised was not 
upgraded during the study period, and the implementation of PS in regression 
analyses of DFS and OS means much of the selection bias is adjusted for. 
Despite the advantages of analysis by PS, the methodology still has 
limitations, principally the inability to adjust for unknown confounding factors10 
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as well as the assumption that the relationship between the propensity score 
and the outcome has been correctly modelled9. Consequently, PS 
implementation in observational studies does not negate the use of 
randomized trials, but rather emphasizes the advantages associated with 
randomization. In clinical situations where randomization may be impractical, 
PS analysis is theoretically a way of minimizing bias to obtain results that may 
approach the level of evidence provided by the rigorous methodology of a 
RCT9,23. PS have two other important strengths. First, if multivariable model 
analyses have traditionally been the preferred statistical method of assessing 
the effect of a predictor variable on outcomes after controlling for baseline 
characteristics, their appropriateness depends on a consistency with several 
assumptions underlying any given model. PS have proven to be the most 
useful statistical method in controlling confounders, providing appropriate 
estimates even when faced with situations of extreme correlation between the 
confounders and the exposure24. Second, PS are well suited if several risk-
adjusted outcomes are under assessment (disease-free and overall survival), 
because the PS simplifies the weighting of multiple outcomes as, once 
calculated, it can be used for each outcome separately. Allied to PS, this 
study has additional strengths, in that it is a large prospective study from a UK 
regional cancer network, with a well-audited practice.16 Accurate state of the 
art radiological staging was utilised by means of PETCT (since 2008) and 
EUS (all patients).11 No patients were lost to follow-up and dates of death 
were obtained from the Office of National Statistics, making the survival data 
especially robust. 
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There have been a number of RCTs comparing NAC followed by 
surgery with surgery alone in the treatment of OC, but conclusions differ. 
Boonstra et al25 from The Netherlands randomized 169 patients to either 
NACS or S, and demonstrated a significant overall 2 and 5 year survival 
advantage following NACS of 12 and 9% respectively, and reported similar 
postoperative morbidity. These results were found despite the fact that the 
disease response rate following chemotherapy (as estimated clinically) was 
poor, with 57% of patients showing stable or progressive disease, and 43% 
showing only partial response. Both Gebski et al26 and Thirion et al27 
published meta-analyses of trials comparing NACS and S. The latter was an 
individual patient data-based meta-analysis, including 9 trials (2,102 patients), 
reported an overall 5 year survival benefit of 4% following NACS compared 
with S (16 vs. 20%, p=0.003)27. Gebski et al compared both CRTS vs. S (10 
studies, 1,209 patients) and NACS vs. S (8 studies, 1,724 patients), and 
reported a 13 and 7% 2-year survival advantage following CRTS and NACS 
respectively. A Cochrane review in 20106, aiming to determine the role of 
preoperative chemotherapy in patients with resectable thoracic oesophageal 
carcinoma, including 12 RCTs and 2,097 patients, concluded that NACS may 
offer a survival advantage but requires further research. It also reported no 
evidence of a difference in rate of resection, tumour recurrence or operative 
morbidity. The Jadad scale was implemented to assess the quality of trials 
included in the review, and two studies were judged to be of high quality and 
low risk of bias, UK MRC OE02 and US RTOG 8911 (USA Intergroup 113) 
trials. MRC OE02 randomised 802 patients to either treatment arm (9% of 
each arm given radiotherapy also) and reported a statistically significantly 
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improved survival in the NACS arm, with 2 and 5 year survival of 34 and 
17.1% following S, and 43 and 23.0% following NACS. RTOG Trial 8911 
however reported equivalence with 2 and 5 year survival of 60 and 20.7% 
following S, and 59 and 19.4% following NACS, consistent with this study. 
RTOG Trial 8911 did however describe a highly significant improvement in 
survival in those NACS patients who demonstrated (by way of barium study) a 
significant response to chemotherapy. Although it was reported that only 19% 
of NACS patients had major objective disease regression, these patients also 
underwent postoperative Radiotherapy, Chemotherapy or 
Chemoradiotherapy, and patients who did not respond proved to have around 
a 10% poorer survival than that of the S patients. In contrast, the 
Chemotherapy responders in this study (demonstrated by pre-operative CT 
and constituting 36.1% of NACS patients) were not found to have improved 
survival compared with the non-responders. Recurrence rates reported in 
RTOG were subdivided related to whether or not a R0 resection had been 
achieved, and demonstrated equivalent recurrence rates following both S and 
NACS. Response to NAC is heterogenous, with TRG correlating with 
survival.28 This study supports the observations made by Noble et al, that only 
16.0% of patients benefit from a good response to NAC, which then translates 
into improved DFS and OS. The onus now is on the cancer network 
community to validate methods of identifying patients who respond favourably 
to NAC, and develop new treatments for non-responders.      
In conclusion, this study has demonstrated similar survival following 
surgery alone and NAC followed by surgery in patients with OC, in keeping 
with the US RTOG trial, but in contrast to the UK MRC OE02. Patients whose 
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disease responded significantly to NAC were in minority (16%), associated 
with improved survival. Previous studies have reported survival benefit and 
improved R0 resection rates following neoadjuvant chemoradiotherapy (CRT), 
albeit at the expense of more operative morbidity, and comparable survival 
has been reported after definitive chemoradiotherapy and multi-modal surgical 
approaches. A current phase 2 study, Neo-SCOPE29, aims to test the safety, 
efficacy and feasibility of patient recruitment to a randomized multi-centre trial 
of pre-operative CRT, as well as selection of the optimum CRT regime. With 
recent advances in the type and use of chemotherapy drugs and radiotherapy 
techniques, CRT may prove to be optimum treatment for potentially 
resectable oesophageal cancer30. Until that time however, the onus should 
now be on identifying patients who derive the most benefit from neoadjuvant 
therapy, because NAC appears to offer limited benefit to the majority of 
patients and risks delay in the most effective part of the multimodal treatment 
i.e. surgery.  
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Table 1. The relationship between neoadjuvant therapy and 
clinicopathological factors 
 Surgery alone 
(n = 176) 
Neoadjuvant 
chemotherapy 
(n = 264) 
p-value 
Pre-operative factors    
Age (years) 
     <65 
     65-75 
     >75 
 
31 (17.6) 
64 (36.4) 
81 (46.9) 
 
67 (25.4) 
133 (50.4) 
64 (24.2) 
<0.001 
Gender  
     Females 
     Males 
 
30 (17.0) 
146 (83.0) 
 
42 (15.9%) 
222 (84.1) 
 
0.752 
ASA 
     2 
     3 
 
76 (43.2) 
100 (56.8) 
 
95 (36.0) 
169 (64.0) 
 
0.129 
Differentiation 
     Well/moderate 
     Poor 
 
63 (64.9) 
24 (20.0) 
 
130 (84.4) 
24 (15.6) 
 
0.323 
Clinical T-stage  
     I 
     II 
     III 
     IV 
 
61 (34.7) 
46 (26.1) 
64 (36.4) 
5 (2.8) 
 
4 (1.5) 
35 (13.3) 
197 (74.6) 
28 (10.6) 
 
<0.001 
Clinical N-stage 
     0 
     I 
     II 
     III 
 
125 (71.0) 
44 (25.0) 
6 (3.4) 
1 (0.6) 
 
83 (32.6) 
151 (57.2) 
22 (8.3) 
5 (1.9) 
 
<0.001 
Clinical TNM stage 
     I 
     IIA 
     IIB 
     III 
     IVA 
 
60 (34.1) 
1 (0.6) 
40 (22.7) 
68 (38.6) 
7 (4.0) 
 
2 (0.8) 
2 (0.8) 
19 (7.2) 
215 (81.4) 
26 (9.8) 
 
<0.001 
Perioperative factors    
Surgery type 
     Ivor-Lewis 
     Trans hiatal 
     Extended gastrectomy 
     Open & close 
 
42 (23.9) 
114 (64.8) 
11 (6.3) 
9 (5.1) 
 
146 (55.3) 
68 (25.8) 
12 (4.5) 
38 (14.4) 
 
<0.001 
pT-stage  
     CR      
     I 
     II 
     III 
     IV 
     No resection 
 
0 (0.0) 
71 (40.3) 
23 (13.1) 
58 (33.0) 
15 (8.5) 
9 (5.1) 
 
10 (3.8) 
18 (6.8) 
22 (8.3) 
156 (59.1) 
20 (7.6) 
38 (14.4) 
 
<0.001 
pN-stage 
     0 
     I 
     II 
     III 
     No resection 
 
99 (56.3) 
41 (23.3) 
18 (10.2) 
9 (5.1) 
9 (5.1) 
 
79 (29.9) 
71 (26.9) 
45 (17.0) 
31 (11.7) 
38 (14.4) 
 
<0.001 
pTNM stage 
     CR      
     I 
     II 
     III 
 
0 (0.0) 
78 (44.3) 
36 (20.5) 
53 (30.1) 
 
11 (4.2) 
27 (10.2) 
49 (18.6) 
139 (52.7) 
 
<0.001 
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     IV 
     No resection 
0 (0.0) 
9 (5.1) 
0 (0.0) 
38 (14.4) 
R-status 
     0 
     1 
     2 
 
120 (68.2) 
47 (26.7) 
9 (5.1) 
 
114 (43.2) 
112 (42.4) 
38 (14.4) 
 
0.001 
Lymph node yield 
(median +/- IQR) 
 
12 (8-17) 
 
15 (12-21)  
 
0.001 
Postoperative morbidity 
     No  
     Yes     
 
80 (45.5) 
96 (54.5) 
 
139 (52.7) 
125 (47.3) 
 
0.139 
Operative mortality 
     No 
     Yes 
 
168 (95.5) 
8 (4.5) 
 
258 (97.7) 
6 (2.3) 
 
0.183 
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Table 2. Univariate and multivariate cox regression survival analysis of factors influencing disease-free survival. 
 
 
 
 
  Univariable 
HR (95% CI) 
  
p-value 
Multivariable 
HR (95% CI) 
  
p-value 
Pre-operative factors 
  
    
Age (<65 / 66-75 / >75 yr.) 1.11 (0.89-1.37) 0.363     
Gender (Female / Male) 1.17 (0.75-1.82) 0.497   
 
ASA (2/3) 0.88 (0.64-1.21) 0.425   
 
Neoadjuvant therapy (No / Yes) 1.76 (1.26-2.46) 0.001   0.220 
Operative factors 
    
Operative Approach (TTO / THO) 0.92 (0.66-1.27) 0.599   
 
Pathological TNM stage (0 / 1 / 2 / 3 / 4) 2.82 (2.21-3.60) <0.001  3.05 (2.12-4.41) <0.001 
Differentiation (Well-moderate / Poor) 2.00 (1.31-3.03) 0.001 
 
0.611 
CRM Margin (Negative / Positive) 2.35 (1.47–3.77) <0.001  0.454 
Lymph Node Yield (<15 / ≥ 15) 0.74 (0.53-1.04) 0.083  0.103 
Propensity scores 5.42 (2.85-10.30) <0.001  0.448 
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Table 3. Univariate and multivariate cox regression survival analysis of factors influencing overall survival. 
 
 
 
 
 
 
 
  Univariable 
HR (95% CI) 
  
p-value 
Multivariable 
HR (95% CI) 
  
p-value 
Pre-operative factors 
  
    
Age (<65 / 66-75 / >75 yr.) 1.16 (0.98-1.37) 0.092    0.207 
Gender (Female / Male) 1.19 (0.84-1.68) 0.333   
 
ASA (2/3) 1.23 (0.95-1.59) 0.122   
 
Neoadjuvant therapy (No / Yes) 1.55 (1.19-2.02) 0.001   0.431 
Operative factors 
    
Operative Approach (TTO / THO) 0.77 (0.58-1.02) 0.072   0.889  
Pathological TNM stage (0 / 1 / 2 / 3 / 4) 2.45 (2.00-3.00) <0.001  3.27 (2.27-4.72) <0.001 
Differentiation (Well-moderate / Poor) 2.22 (1.54-3.19) <0.001 
 
0.125 
CRM Margin (Negative / Positive) 3.15 (2.05–4.82) <0.001  0.655 
Lymph Node Yield (<15 / ≥ 15) 0.91 (0.69-1.21) 0.528   
Propensity scores 6.17 (3.48-10.94) <0.001  0.202 
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Fig. 1 (a). Cumulative disease-free survival related to treatment modality. (b) 
Cumulative overall survival related to treatment modality  		
Fig. 2 (a). Cumulative disease-free survival related to Mandard TRG. (b) 
Cumulative overall survival related to Mandard TRG  
 
